Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2018

Zhang Lingjun, Sorensen Mia D, Kristensen Bjarne W, Reifenberger Guido, McIntyre Thomas M, Lin Feng

Abstract excerpt

Purpose: Somatic mutations in the isocitrate dehydrogenase (IDH)-1 and -2 genes are remarkably penetrant in diffuse gliomas. These highly effective gain-of-function mutations enable mutant IDH to efficiently metabolize isocitrate to D-2-hydroxyglutarate (D 2-HG) that accumulates to high concentrations within the tumor microenvironment. D 2-HG is an intracellular effector that promotes tumor growth through...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytes
Share to Complement Activation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement System Proteins

Share to Cytotoxicity, Immunologic

Share to Dendritic Cells

Share to Glutarates

Share to Neoplasm Grading

Share to Phagocytosis

Source

Open in PubMed Open full text

Identifiers

PMID: 30006485
DOI: 10.1158/1078-0432.CCR-17-3855
PMCID: PMC6214730

Genes

FOXP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.PMID 30006485Read ↗

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.Semantic proximity Read ↗

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.Semantic proximity Read ↗

Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.Semantic proximity Read ↗

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.Semantic proximity Read ↗

IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression.Semantic proximity Read ↗

Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomasSemantic proximity Read ↗

Mutant IDH1 regulates the tumor-associated immune system in gliomas.Semantic proximity Read ↗

Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma.Semantic proximity Read ↗

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.Semantic proximity Read ↗

The Predictive and Therapeutic Role of Complement in GliomasSemantic proximity Read ↗

D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.